Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Lymphoid 1

Conditions

Multiple Myeloma 145Lymphoma, Follicular 41Lymphoma, Large B-Cell, Diffuse 36Lymphoma, B-Cell, Marginal Zone 24Recurrence 17Lymphoma, Mantle-Cell 17Lymphoma 16Neoplasms, Plasma Cell 15Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 11Neoplasms 9Lymphoma, B-Cell 8Smoldering Multiple Myeloma 7Burkitt Lymphoma 5Neoplasm, Residual 4Leukemia, Plasma Cell 4Waldenstrom Macroglobulinemia 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Plasmacytoma 2Pancreatic Neoplasms 2Neuroblastoma 2Lymphoma, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Hodgkin Disease 2Hematologic Diseases 2Urinary Bladder Neoplasms 1

Interventions

Cyclophosphamide 12fludarabine phosphate 7fludarabine 7venetoclax 6blinatumomab 6Cytarabine 5Lenalidomide 4Dexamethasone 4Blood Specimen Collection 4Azacitidine 4obinutuzumab 3Rituximab 3Radiotherapy 3Melphalan 3Immunotherapy, Adoptive 3pembrolizumab 2daratumumab 2Neoadjuvant Therapy 2Idarubicin 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sacituzumab govitecan 1sabatolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm, Residual × Lenalidomide × 1 year × Clear all
NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Weill Medical College of Cornell University

Phase 2 Active not recruiting
37 enrolled 9 charts
Lymphoid

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting
30 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT02389517 2026-01-22

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

University of Chicago

Phase 2 Completed
42 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

University of Alabama at Birmingham

Phase 2 Recruiting
40 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡